Lumida
/SGHT
⌘K
Sight Sciences Inc

Sight Sciences Inc

SGHT
$5.03USD↓-3.27%-0.17 today

MARKET CAP

273.7M

P/E (TTM)

—

FWD P/E

—

DAY RANGE

$5 – $5

52W RANGE

$3
$9

AI Summary

Stalk
Buy NowMedium

SGHT remains in a Stage 2 advancing phase, underpinned by an active Lockout Rally that has driven price above the 9 and 21 EMAs on rising volume. The medium-term bias is bullish, supported by a HH/HL sequence off the March low, while the long-term trend stays intact. Short-term execution is favorable now under the Lockout Rally override, so participation at shallow pullbacks into the EMAs aligns with continuation dynamics.

  • ↑Q1 2026 revenue $19.7M, up 13% YoY across glaucoma and dry eye.
  • ↑Raised 2026 revenue guidance to $83–89M, implying 7–15% growth.
  • ↓Negative earnings yield and profitability factors signal weak returns.
Full analysis →

The case for & against

Bull & Bear analysis

Bearish

Sight Sciences, Inc. (NASDAQ: SGHT) operates in the ophthalmic medical technology sector, specializing in innovative interventional treatments for glaucoma and dry eye diseases. With a focus on advancing surgical procedures through minimally invasive techniques, the company aims to become a leader in ocular interventions that significantly improve patient care. Sight Sciences is positioned to capitalize on the growing demand for effective eye care solutions, leveraging its innovative product pipeline, including the Omni and TierCare systems.

Bull says

  • ↑Q1 2026 revenue $19.7M, up 13% YoY across glaucoma and dry eye.
  • ↑Raised 2026 revenue guidance to $83–89M, implying 7–15% growth.
  • ↑Gross margin strong at 86% (glaucoma 87%), reflecting pricing power.
  • ↑OmniUltra launch expected shortly to strengthen glaucoma market share.
  • ↑Engaging Medicare contractors to secure TierCare reimbursement expands access.
  • ↑Positive momentum factors support potential upside in share performance.

Bear says

  • ↓Negative earnings yield and profitability factors signal weak returns.
  • ↓Q1 net loss $13M ($0.24/sh) despite 13% revenue growth.
  • ↓Volatility high, short interest elevated, liquidity remains low.
  • ↓Reimbursement delays risk commercial adoption of new treatments.
  • ↓New MIGS entrants intensify competition, pressuring market share.
  • ↓Elevated size risk and strained path to profitability.

Earnings Call · Q1 2026 · Mgmt. Guidance

Updated 05-12-2026neutral

Transcript signals

Bull points

  • 6,500 ECPs fall into that bucket as kind of that initial target population. Within First Coast and Novitas, there's 2,000 ECPs that would meet that same criteria. So we are still very small.
  • we're in a really good spot with a really healthy balance sheet and a strong pathway to cash flow break-even and While at the same time having the ability to go invest in these two significant opportunities.
  • The balance for us is we want to make disciplined, high return investments. And we're fortunate, I think, to have the flexibility to go faster on some of those investments where there's outsized opportunity for growth.

Bear points

  • We have not received any cash to date and we will not book anything, obviously, until such time when appeals would be exhausted and cash would change hands, for example.
  • we still expect to have additional payer wins in 2026 it is hard to predict exact timing there but we we fundamentally don't feel any different about our ability to get payer wins over time here to get access to this technology for our patients and our ECP provider partners.
  • we still expect to have additional payer wins in 2026 it is hard to predict exact timing there but we we fundamentally don't feel any different about our ability to get payer wins over time here to get access to this technology for our patients and our ECP provider partners.
Read full transcript analysis ›